Last reviewed · How we verify

IM Ketamine — Competitive Intelligence Brief

IM Ketamine (IM Ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Psychiatry / Pain Management.

phase 3 NMDA receptor antagonist NMDA receptor Psychiatry / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

IM Ketamine (IM Ketamine) — Tel-Aviv Sourasky Medical Center. IM Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist administered intramuscularly that produces rapid-onset dissociative anesthesia and analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IM Ketamine TARGET IM Ketamine Tel-Aviv Sourasky Medical Center phase 3 NMDA receptor antagonist NMDA receptor
Namenda MEMANTINE AbbVie marketed N-methyl-D-aspartate Receptor Antagonist Glutamate NMDA receptor; GRIN1/GRIN2A 2003-01-01
Felbatol FELBAMATE Mylan Speciality Lp marketed Anti-epileptic Agent [EPC] NMDA receptor-ionophore complex 1993-01-01
QUINIDINE QUINIDINE marketed sigma-1 receptor, NMDA receptor, CYP2D6 1950-01-01
Methadone Hydrochloride METHADONE Specgx Llc marketed Opioid Agonist mu-opioid receptors, NMDA receptor 1947-01-01
Lidocaine/Magnesium Lidocaine/Magnesium University of Wisconsin, Madison marketed Local anesthetic combination Voltage-gated sodium channels; NMDA receptor
Intravenous Ketamine Intravenous Ketamine Rebecca Price marketed Dissociative anesthetic NMDA receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

  1. Turku University Hospital · 3 drugs in this class
  2. H. Lundbeck A/S · 2 drugs in this class
  3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
  4. Shalvata Mental Health Center · 2 drugs in this class
  5. New York State Psychiatric Institute · 2 drugs in this class
  6. Auris Medical AG · 1 drug in this class
  7. AstraZeneca · 1 drug in this class
  8. Alameda Health System · 1 drug in this class
  9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
  10. Asker & Baerum Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IM Ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/im-ketamine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: